PMID- 30766809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 22
IP  - 6
DP  - 2018 Nov-Dec
TI  - Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence 
      from a Tertiary Care Diabetes Center in India.
PG  - 728-734
LID - 10.4103/ijem.IJEM_424_18 [doi]
AB  - AIMS: To evaluate the real-world efficacy, durability, and side-effect profile of 
      once weekly GLP1RA: dulaglutide in Indian type 2 diabetes mellitus (T2DM) 
      patients. MATERIALS AND METHODS: A retrospective observational study. Data for 
      efficacy (HbA1c and weight), adherence/discontinuation and patient reported 
      side-effects, of 117 patients who were prescribed dulaglutide were analyzed. 
      RESULTS: Final analysis was done on complete data of 74 patients (6 months 
      follow-up), this indicated that dulaglutide is effective (mean-reduction at 6 
      months of: HbA1c; 0.87% and weight; 3.8 kg). Subjects with a poorer glycemic 
      control (greater HbA1c) or greater weight at initiation had a better fall in 
      HbA1c and weight reduction at the end of the study. The most common side-effects 
      were gastrointestinal (15% nausea and 6% loose motions). Also, 25% (n = 19) of 
      our study subjects discontinued dulaglutide because of gastrointestinal 
      side-effects. CONCLUSION: Our real-world experience is well aligned to systematic 
      data of the randomized controlled trials (RCTs) regarding the efficacy of 
      dulaglutide in the treatment of T2DM (our study vs. RCTs; HbA1c reduction: 0.87% 
      vs. 0.78% to 1.64%, weight reduction: 3.8 vs. 0.3 to 3 kg). The most common 
      side-effects and reason for discontinuation were gastrointestinal side-effects. 
      Finally, by virtue of their observed benefit, we expect a superior cardiovascular 
      risk-reduction with dulaglutide use in our population.
FAU - Wasir, Jasjeet S
AU  - Wasir JS
AD  - Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurugram, Haryana, 
      India.
FAU - Mithal, Ambrish
AU  - Mithal A
AD  - Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurugram, Haryana, 
      India.
FAU - Agarwal, Paras
AU  - Agarwal P
AD  - Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurugram, Haryana, 
      India.
FAU - Mittal, Apeksha
AU  - Mittal A
AD  - Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurugram, Haryana, 
      India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC6330857
OTO - NOTNLM
OT  - Dulaglutide
OT  - real-world experience
OT  - type 2 diabetes mellitus
COIS- There are no conflicts of interest.
EDAT- 2019/02/16 06:00
MHDA- 2019/02/16 06:01
PMCR- 2018/11/01
CRDT- 2019/02/16 06:00
PHST- 2019/02/16 06:00 [entrez]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2019/02/16 06:01 [medline]
PHST- 2018/11/01 00:00 [pmc-release]
AID - IJEM-22-728 [pii]
AID - 10.4103/ijem.IJEM_424_18 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):728-734. doi: 
      10.4103/ijem.IJEM_424_18.